100 related articles for article (PubMed ID: 18991686)
1. Pharmacogenetics and pharmagenomics, trends in normal and pathological aging studies: focus on p53.
Lanni C; Racchi M; Uberti D; Mazzini G; Stanga S; Sinforiani E; Memo M; Govoni S
Curr Pharm Des; 2008; 14(26):2665-71. PubMed ID: 18991686
[TBL] [Abstract][Full Text] [Related]
2. p53 at the crossroads between cancer and neurodegeneration.
Lanni C; Racchi M; Memo M; Govoni S; Uberti D
Free Radic Biol Med; 2012 May; 52(9):1727-33. PubMed ID: 22387179
[TBL] [Abstract][Full Text] [Related]
3. The interactions of p53 with tau and Aß as potential therapeutic targets for Alzheimer's disease.
Jazvinšćak Jembrek M; Slade N; Hof PR; Šimić G
Prog Neurobiol; 2018 Sep; 168():104-127. PubMed ID: 29733887
[TBL] [Abstract][Full Text] [Related]
4. Intracellular Abeta42 activates p53 promoter: a pathway to neurodegeneration in Alzheimer's disease.
Ohyagi Y; Asahara H; Chui DH; Tsuruta Y; Sakae N; Miyoshi K; Yamada T; Kikuchi H; Taniwaki T; Murai H; Ikezoe K; Furuya H; Kawarabayashi T; Shoji M; Checler F; Iwaki T; Makifuchi T; Takeda K; Kira J; Tabira T
FASEB J; 2005 Feb; 19(2):255-7. PubMed ID: 15548589
[TBL] [Abstract][Full Text] [Related]
5. Conformationally altered p53: a novel Alzheimer's disease marker?
Lanni C; Racchi M; Mazzini G; Ranzenigo A; Polotti R; Sinforiani E; Olivari L; Barcikowska M; Styczynska M; Kuznicki J; Szybinska A; Govoni S; Memo M; Uberti D
Mol Psychiatry; 2008 Jun; 13(6):641-7. PubMed ID: 17684496
[TBL] [Abstract][Full Text] [Related]
6. Unfolded p53: a potential biomarker for Alzheimer's disease.
Lanni C; Uberti D; Racchi M; Govoni S; Memo M
J Alzheimers Dis; 2007 Aug; 12(1):93-9. PubMed ID: 17851197
[TBL] [Abstract][Full Text] [Related]
7. Alzheimer's disease.
De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
[TBL] [Abstract][Full Text] [Related]
8. Identification of a mutant-like conformation of p53 in fibroblasts from sporadic Alzheimer's disease patients.
Uberti D; Lanni C; Carsana T; Francisconi S; Missale C; Racchi M; Govoni S; Memo M
Neurobiol Aging; 2006 Sep; 27(9):1193-201. PubMed ID: 16165254
[TBL] [Abstract][Full Text] [Related]
9. The pleiotropic role of p53 in functional/dysfunctional neurons: focus on pathogenesis and diagnosis of Alzheimer's disease.
Abate G; Frisoni GB; Bourdon JC; Piccirella S; Memo M; Uberti D
Alzheimers Res Ther; 2020 Dec; 12(1):160. PubMed ID: 33272326
[TBL] [Abstract][Full Text] [Related]
10. Expression of Aβ42, τ-Protein, p16, p53 in Buccal Epithelium: Prospects for Use in the Diagnostics of Alzheimer's Disease and Rate of Aging.
Zuev VA; Dyatlova AS; Lin'kova NS; Kvetnaya TV
Bull Exp Biol Med; 2019 Mar; 166(5):676-679. PubMed ID: 30903490
[TBL] [Abstract][Full Text] [Related]
11. Unfolded p53 in the pathogenesis of Alzheimer's disease: is HIPK2 the link?
Stanga S; Lanni C; Govoni S; Uberti D; D'Orazi G; Racchi M
Aging (Albany NY); 2010 Sep; 2(9):545-54. PubMed ID: 20876941
[TBL] [Abstract][Full Text] [Related]
12. Impact of aging: sporadic, and genetic risk factors on vulnerability to apoptosis in Alzheimer's disease.
Schindowski K; Kratzsch T; Peters J; Steiner B; Leutner S; Touchet N; Maurer K; Czech C; Pradier L; Frölich L; Müller WE; Eckert A
Neuromolecular Med; 2003; 4(3):161-78. PubMed ID: 14716024
[TBL] [Abstract][Full Text] [Related]
13. Wild-type but not Alzheimer-mutant amyloid precursor protein confers resistance against p53-mediated apoptosis.
Xu X; Yang D; Wyss-Coray T; Yan J; Gan L; Sun Y; Mucke L
Proc Natl Acad Sci U S A; 1999 Jun; 96(13):7547-52. PubMed ID: 10377452
[TBL] [Abstract][Full Text] [Related]
14. Molecular genetics of Alzheimer's disease and aging.
Cacabelos R; Fernandez-Novoa L; Lombardi V; Kubota Y; Takeda M
Methods Find Exp Clin Pharmacol; 2005 Jul; 27 Suppl A():1-573. PubMed ID: 16470248
[TBL] [Abstract][Full Text] [Related]
15. A novel mechanism of non-Aβ component of Alzheimer's disease amyloid (NAC) neurotoxicity. Interplay between p53 protein and cyclin-dependent kinase 5 (Cdk5).
Kaźmierczak A; Czapski GA; Adamczyk A; Gajkowska B; Strosznajder JB
Neurochem Int; 2011 Feb; 58(2):206-14. PubMed ID: 21130128
[TBL] [Abstract][Full Text] [Related]
16. Highly pathogenic Alzheimer's disease presenilin 1 P117R mutation causes a specific increase in p53 and p21 protein levels and cell cycle dysregulation in human lymphocytes.
Bialopiotrowicz E; Szybinska A; Kuzniewska B; Buizza L; Uberti D; Kuznicki J; Wojda U
J Alzheimers Dis; 2012; 32(2):397-415. PubMed ID: 22810102
[TBL] [Abstract][Full Text] [Related]
17. Homocysteine and folate deficiency sensitize oligodendrocytes to the cell death-promoting effects of a presenilin-1 mutation and amyloid beta-peptide.
Pak KJ; Chan SL; Mattson MP
Neuromolecular Med; 2003; 3(2):119-28. PubMed ID: 12728194
[TBL] [Abstract][Full Text] [Related]
18. Hippocampal administration of chondroitinase ABC increases plaque-adjacent synaptic marker and diminishes amyloid burden in aged APPswe/PS1dE9 mice.
Howell MD; Bailey LA; Cozart MA; Gannon BM; Gottschall PE
Acta Neuropathol Commun; 2015 Sep; 3():54. PubMed ID: 26337292
[TBL] [Abstract][Full Text] [Related]
19. Multiple faces of dynamin-related protein 1 and its role in Alzheimer's disease pathogenesis.
Kandimalla R; Reddy PH
Biochim Biophys Acta; 2016 Apr; 1862(4):814-828. PubMed ID: 26708942
[TBL] [Abstract][Full Text] [Related]
20. Conformationally altered p53: a putative peripheral marker for Alzheimer's disease.
Uberti D; Lanni C; Racchi M; Govoni S; Memo M
Neurodegener Dis; 2008; 5(3-4):209-11. PubMed ID: 18322392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
